Search clinical trials for: GRN163L

Total 17 results

Geron Corporation

Completed

Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

Chronic Lymphoproliferative Diseases

United States
Geron Corporation

Completed

A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer

Breast Cancer

United States
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)

Terminated

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

Glioblastoma | Gliosarcoma | Ependymoma | Anaplastic Astrocytoma | Oligodendroglioma | Anaplastic Ependymoma | Giant Cell Glioblastoma | Astrocytoma, Grade II | Brainstem Tumors

United States
Children's Oncology Group
National Cancer Institute (NCI)

Withdrawn

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Rhabdomyosarcoma | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Hepatoblastoma | Recurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Recurrent Childhood Liver Cancer
Geron Corporation

Completed

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis | Myeloid Malignancies

United States
Geron Corporation

Active, not recruiting

Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States, Canada, Belgium, Spain, Czechia, Korea, Republic of, United Kingdom, Netherlands, Israel, Germany, Russian Federation, Switzerland, Italy, France, Turkey, Poland, Ukraine
Geron Corporation

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

Myelofibrosis

United States
GCP-Service International West GmbH
Saint-Louis Hospital, Paris, France; Groupe Francophone des Myelodysplasies; Australasian... and other collaborators

Recruiting

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Australia, France, Germany
Geron Corporation

Completed

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

Multiple Myeloma

United States
Geron Corporation

Completed

Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies

Solid Tumor Malignancies

United States
Geron Corporation

Completed

Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer

Lung Cancer

United States
Indiana University
Breast Cancer Research Foundation; Geron Corporation

Completed

A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer

Breast Neoplasms

United States
Geron Corporation

Completed

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

Multiple Myeloma

United States
Geron Corporation

Recruiting

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Myelofibrosis

United States, Australia, Italy, India, United Kingdom, Israel, Taiwan, Poland, Malaysia, Argentina, Spain, Turkey, Belgium, Germany, Austria, Brazil, Bulgaria, Colombia, Denmark, France, Georgia, Hungary, Korea, Republic of, Portugal, ... and more
Geron Corporation

Completed

Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Canada, Germany
Geron Corporation

Completed

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Locally Recurrent or Metastatic Breast Cancer

United States, Canada
Geron Corporation

Completed

Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma

Multiple Myeloma

United States

Search clinical trials for: GRN163L

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations